Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30085037 | 0.88 | HRH3 (0.40) | TERTHRH3S1PR1S1PR3S1PR5 | |
| SCHEMBL9893118 | 0.85 | MEN1 (0.41) | HRH3S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL16480467 | 0.82 | HRH3 (0.55) | HRH3 | |
| SCHEMBL9891878 | 0.81 | HRH3 (0.41) | HRH3HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL15025236 | 0.79 | HSD17B10 (0.42) | HRH3HSD17B10 | |
| SCHEMBL16194551 | 0.79 | HSD17B10 (0.42) | HRH3HSD17B10 | |
| SCHEMBL4028869 | 0.79 | EPHX1 (0.46) | HRH3OPRD1HSD17B10L3MBTL1TSHR | |
| SCHEMBL9892347 | 0.78 | HRH3 (0.39) | HRH3TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL24757306 | 0.76 | HRH3 (0.41) | TERTHRH3S1PR1S1PR3S1PR5 | |
| SCHEMBL12788353 | 0.73 | MAPK1 (0.35) | TERTHRH3S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | TERT 4831/4885HRH3 236/4885S1PR1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.